Skip to content

Impact of lipid-lowering therapy with Evolocumab on coronary plaque regression in patients with coronary artery disease

Impact of lipid-lowering therapy with Evolocumab on coronary plaque regression in patients with coronary artery disease - Impact of Evolocumab on coronary plaque regression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000023448
Enrollment
25
Registered
2016-08-30
Start date
2016-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with coronary artery disease requiring percutaneous coronary intervention (PCI), and with LDL-C &gt

Interventions

Intravascular ultrasound (and optical coherence tomography, if possible) will be performed to observe coronary plaque of non-culprit lesions at follow-up coronary angiography 12 months after stent imp

Sponsors

Chiba University Graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with coronary artery disease requiring percutaneous coronary intervention 2) Patients with LDL-C >= 100 mg/dl even on statin therapy for at least 4 weeks, either with or without familial hypercholesterolemia 3) 20 to 85 years old 4) Signed written informed consent

Exclusion criteria

Exclusion criteria: 1) Difficulty to observe the coronary arteries, including non-culprit lesions, by IVUS at PCI procedure 2) Severe hepatic insufficiency 3) Severe renal insufficiency 4) Severe heart failure (left ventricular ejection fraction <30%, or NYHA class III or IV) 5) intolerance or allergy to statin 6) Pregnant, postpartum within 28 days, or breast-feeding 7) Recognized as inadequate by attending doctor

Design outcomes

Primary

MeasureTime frame
Change in percent atheroma volume (PAV) in non-culprit lesions from baseline to follow-up (12 months after PCI) as measured by intravascular ultrasound (IVUS)

Countries

Japan

Contacts

Public ContactHideki Kitahara

Chiba University Graduate School of Medicine Department of Cardiovascular Medicine

hkitahara@chiba-u.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026